Merck says its molnupiravir drug, developed along with Ridgeback Biotherapeutics, shows antiviral properties against coronavirus variants such as the Delta variant
The oral antiviral Molnupiravir is going to be supplied by five Indian pharmaceutical companies who have signed licensing agreements with the parent company